Mulberry Leaf Extract for NAFLD / MASLD

Verdict: No human evidence for fatty liver

There is currently no human evidence that mulberry leaf extract treats non-alcoholic fatty liver disease (NAFLD/MASLD). Every supportive finding comes from animal or cell-based studies, so its benefit for the human liver remains unproven.

U ⚫ U Unverified Insufficient Evidence

🔬Why this grade7-layer evidence engine

This pairing is rated Unverified because all five available studies are preclinical, with zero human randomized trials measuring liver-specific outcomes. Mouse models consistently showed mulberry leaf preparations lowering liver fat and ALT/AST and easing inflammation (PMID 41431350, PMID 38488910, PMID 32948162), and a cell-line study found a DNJ-rich extract reduced fat accumulation in hepatocytes (PMID 41462942). One frequently grouped study (PMID 34035824) is actually an alcoholic-liver model, not NAFLD, so it does not even apply here.

The translational gap is the core problem. Animal and cell results often fail to reproduce in people, doses across the studies are inconsistent, and existing human mulberry trials looked at blood sugar rather than the liver. Regulators reflect this: the EU EFSA states a cause-and-effect relationship cannot be established and the extract is 'not sufficiently characterised,' while major clinics and the AASLD NAFLD guideline do not mention mulberry at all, recommending only vitamin E and pioglitazone.

A safety note matters because many people with NAFLD also have type 2 diabetes. The NIH/NCCIH cautions that white mulberry may lower blood glucose and warns of 'a potential risk for low blood sugar when taken with diabetes medications.' Until controlled human liver trials exist, mulberry leaf should not be relied on to treat fatty liver; proven steps are weight loss, a Mediterranean diet, and limiting alcohol.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.44
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
84%
Highly consistent evidence
Evidence level
E10
Mechanism / case reports / no human evidence

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.20
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.44
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 僅有 E10 級證據 (cohort/animal/mechanism),不足以下結論
  4. tier_strict_requirement_check — C 級條件未達 (需 E1-E8;實際 E10 僅機轉)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Ultrafiltered mulberry leaf glutelin mitigates non-alcoholic fatty liver disease through modulation of lipid metabolism, inflammation, and serum metabolomics
PMID: 41431350 2026 Animal Study
Finding: UF-MLG reduced ALT/AST, improved lipid profile, decreased pro-inflammatory cytokines; ameliorated hepatic steatosis in HFD mice
View on PubMed
Improving the Effects of Mulberry Leaves and Neochlorogenic Acid on Glucotoxicity-Induced Hepatic Steatosis in High Fat Diet Treated db/db Mice
PMID: 38488910 2024 Animal Study
Finding: MLWE reduced serum lipid profile and hepatic lipid deposition; attenuated glucotoxicity-induced hepatic steatosis
View on PubMed
Effect of Mulberry Leaf and Its Active Component, 1-Deoxynojirimycin, on Palmitic Acid-Induced Lipid Accumulation in HepG2 Cells
PMID: 41462942 2026 In vitro
Finding: DNJ-rich mulberry leaf extract reduced palmitic acid-induced lipid accumulation in HepG2 hepatocytes
🟠 Limited quality
View on PubMed
Aqueous Mulberry Leaf Extract Ameliorates Alcoholic Liver Injury Associating with Upregulation of Ethanol Metabolism and Suppression of Hepatic Lipogenesis
PMID: 34035824 2021 Animal Study
Finding: Reduced hepatic lipid accumulation, upregulated ethanol metabolism, suppressed lipogenesis; alcoholic (not non-alcoholic) liver model
🟠 Limited quality
View on PubMed
Fermented mulberry (Morus alba) leaves suppress high fat diet-induced hepatic steatosis through amelioration of the inflammatory response and autophagy pathway
PMID: 32948162 2020 Animal Study
Finding: Decreased hepatic lipid droplets, reduced mast cell infiltration and inflammatory mediators; modulated autophagy pathway
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
L4b EU EFSA
Not addressed
A cause and effect relationship cannot be established between the consumption of Morus alba (white mulberry) leaf extract and the claimed effect. The mulberry extract is not sufficiently characterised in relation to the claimed effect. The proposed target population of diabetic patients does not comply with the criteria for disease risk reduction claims. source↗
L4d TW TFDA / 衛福部
Supportive
本產品經動物實驗結果證實:有助於延緩飯後血糖上升,僅供參考。本產品經動物實驗結果證實:有助於降低體脂肪形成(不易形成體脂肪),僅供參考。 source↗
L5a NIH Office of Dietary Supplements
Cautious
Several studies suggest that white mulberry may reduce elevated blood glucose levels, but some of these studies have been preliminary or were not conducted in humans. Other trials have found no effect on blood glucose levels. There is a potential risk for low blood sugar when taken with diabetes medications. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-nafld-INT-mulberry-leaf-extract-001 繁體中文版 →